Summit Therapeutics (SMMT) Reports Q1 Loss of GBP0.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
June 2, 2016 7:01 AM EDTOXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today reports its financial results for the first quarter ended 30 April 2016. Â Â
Mr Glyn Edwards, Chief Executive Officer of Summit commented: Our programmes in DMD and CDI both have the potential to significantly improve the current standards of care and are making good progress towards the patients who could... More
Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
May 31, 2016 7:00 AM EDTOXFORD, United Kingdom, May 31, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the... More
